Healthy Lactobacillus bacteria in the vagina are critical for women's health, but the accumulation of additional bacterial genera can imbalance the vaginal ecosystem. Such an imbalance may result in bacterial metabolism of drugs designed to prevent HIV infection, thereby decreasing their effectiveness and enhancing risks to women, according to a study published December 3, 2020 in the open-access journal PLOS Pathogens by Dr. Nichole Klatt of the University of Minnesota Medical School, and colleagues.
Dolutegravir, the current first-line treatment for HIV, may not be as effective as hoped in sub-Saharan Africa, suggests new research published on World AIDS Day. The study finds that this so-called 'wonder drug' may be less effective in patients resistant to older drugs.
Lehigh University Professor Kelly Austin explores the consequences of drought and lack of environmental resources on women in less-developed countries. The research shows the direct and indirect associations to women's percentage of HIV.
Taking a major step forward in HIV research, scientists at the Lewis Katz School of Medicine at Temple University have successfully edited SIV - a virus closely related to HIV, the cause of AIDS - from the genomes of non-human primates. The breakthrough brings Temple researchers and their collaborators closer than ever to developing a cure for human HIV infection.
A team co-led by a scientist at the University of California, Riverside, has developed a method to study how HIV mutates to escape the immune system in multiple individuals, which could inform HIV vaccine design.
The number of people living with undiagnosed HIV is increasing in the WHO European Region. According to data published today by ECDC and the WHO/Europe, more than 136 000 people were newly diagnosed in 2019 - roughly 20% of these diagnoses were in the EU/EAA and 80% in the eastern part of the European Region. Every second HIV diagnosis (53%) happens at a late stage of the infection, when the immune system has already started to fail.
A new therapy for influenza virus infections that may also prove effective against many other pathogenic virus infections, including HIV and COVID-19, has been developed by Purdue University scientists. The Purdue team's approach uses a targeted therapy approach against the virus infections.
Sexually-active over-45s are at a high risk of contracting STIs because people do not want to talk about holder people having sex, a report has found.
Unlike so many other deadly viruses, HIV still lacks a vaccine. The virus has proven especially tricky to prevent with conventional antibodies, in part because it evolves so rapidly in the body. A solution would require coaxing the body into producing a special type of antibody that can act broadly to defeat multiple strains of the virus at once. Scientists at Scripps Research moved closer to attaining that goal with an approach that would rely on genetically engineered immune cells from the patient's body.
it is increasingly clear how Nef manages to subvert human cells' defense mechanisms, enabling HIV to replicate and bringing the symptoms of AIDS closer.